Attached files

file filename
8-K - 8-K Q1 2020 EARNINGS PRESS RELEASE - GENTHERM Incthrm-8k_20200507.htm
EX-99.2 - EX-99.2 - GENTHERM Incthrm-ex992_199.htm

Exhibit 99.1

 

Gentherm Reports 2020 First Quarter Results

 

Significantly Improved Net Cash from Operating Activities

Strong Total Liquidity of $450 Million at Quarter End

Maintained Gross Margin Rate at Similar Levels Despite Market Challenges

 

NORTHVILLE, Michigan, May 7, 2020 /Global Newswire/ -- Gentherm (NASDAQ:THRM), the global market leader and developer of innovative thermal management technologies, today announced its financial results for the first quarter ending March 31, 2020.

First Quarter Highlights

 

Product revenues of $228.6 million decreased 11.4% from $257.9 million in the 2019 first quarter.

 

o

Excluding the impact of foreign currency translation, product revenues decreased 10.1% year over year; excluding the impact of foreign currency translation and divested assets, product revenues decreased 7.5% year over year

 

GAAP diluted earnings per share was $0.36 as compared with $0.25 for the prior-year period

 

Adjusted diluted earnings per share (see table herein) was $0.51. Adjusted diluted earnings per share in the prior-year period was $0.55

 

Net cash provided by operating activities was $29.4 million as compared with $6.9 million in the prior-year period

 

Secured automotive new business awards totaling $120 million in the quarter

 

Achieved record quarterly revenue of $12.1 million in Gentherm Medical; increased 48.3% year over year

Phil Eyler, the Company's President and CEO, said “Despite the unprecedented challenges in our markets presented by the worldwide pandemic, we delivered solid financial results in the first quarter. We continued to outperform in Automotive versus the key markets we serve and achieved record quarterly revenue in our Medical business. In addition, we generated a significant increase in cash flow versus the prior-year period.

 

“I am proud that our Blanketrol® solutions are supporting temperature management of COVID-19 patients, improving outcomes. In addition, we are partnering with Ford to design and manufacture components for powered air-purifying respirators (PAPRs) as part of the response to the pandemic.”

 

He continued, “While the COVID-19 pandemic has created significant challenges and uncertainties in the near term, the actions we have taken since launching our Focused Growth strategy, including our ongoing disciplined approach to managing expenses and the divestiture of non-core assets, has strengthened our balance sheet and positions us well to overcome the current challenges and to deliver over the long term.”

 

2020 First Quarter Financial Review

Product revenues for the first quarter of 2020 decreased $29.3 million, or 11.4%, as compared with the prior-year period. Excluding the impact of foreign currency translation and divested assets, product revenues decreased 7.5% year over year. The estimated net negative impact of the COVID-19 pandemic on product revenues was $27 million.

 


 

Automotive revenues declined 10.7% year over year. The revenue increase in Steering Wheel Heaters and Battery Thermal Management (BTM) was more than offset by revenue decreases in all other product categories. Adjusting for foreign currency translation, organic Automotive revenues decreased 9.4% year over year. The estimated negative impact of the COVID-19 pandemic on Automotive revenues was $28 million.

According to IHS Markit, actual light vehicle production declined by approximately 24% when compared to the first quarter of 2019 in the Company’s key markets of North America, Europe, China, Japan and Korea. The decrease in the Company’s organic Automotive revenues was significantly less than the decline in light vehicle production during the quarter. Adjusting for Gentherm’s lower revenue exposure in China, the Company outperformed actual light vehicle production by approximately 560 basis points.

The 22.0% revenue decrease in Industrial resulted from the divestitures of the Cincinnati Sub-Zero industrial chambers business (“CSZ-IC”), which was sold on February 1, 2019 and Global Power Technologies (“GPT”), which was sold on October 1, 2019. The decrease was partially offset by year-over-year growth of 48.3% in Gentherm Medical, primarily due to the acquisition of Stihler on April 1, 2019 and increased demand for our Blanketrol® solutions to support temperature management of COVID-19 patients.

See the “Revenues by Product Category” table included below for additional detail.

Gross margin rate decreased slightly to 28.9% in the current-year period, as compared with 29.2% in the prior-year period, primarily as a result of annual customer price reductions and lower Automotive volume due to the COVID-19 pandemic. These were partially offset by improved labor productivity at the manufacturing facilities, supplier cost reductions, and positive sales mix as a result of the strength in our Medical business.

Net research and development expenses of $17.8 million in the 2020 first quarter decreased $1.1 million, or 6.0%. R&D expenses decreased year over year, as a direct result of the Company’s focused portfolio and cost reduction initiatives.

Selling, general and administrative expenses of $25.9 million in the 2020 first quarter decreased $6.8 million, or 20.9%, versus the prior-year period. The year-over-year decrease was primarily driven by the divestiture of the Industrial businesses, lower stock compensation costs as a result of mark to market revaluation of stock appreciation rights, CFO transition costs in the prior-year period and other cost reduction initiatives.

During the quarter, the Company recognized $3.8 million in restructuring expenses which resulted from actions associated with restructuring plans to improve manufacturing productivity and other initiatives.

As described more fully in the table included below, “Reconciliation of Net Income to Adjusted EBITDA,” the Company recorded Adjusted EBITDA of $32.7 million in the 2020 first quarter compared with $35.2 million in the prior-year period, a decrease of $2.5 million or 7.1%.

Income tax expense in the 2020 first quarter was $5.4 million, as compared with $6.9 million in the prior-year period. The effective tax rate of 31.3% differed from the Federal statutory rate of 21%, primarily due to higher taxes on foreign earnings.

GAAP diluted earnings per share for the first quarter of 2020 was $0.36 compared with $0.25 for the prior-year period. Adjusted diluted earnings per share, excluding restructuring expenses and unrealized currency losses (see table herein), was $0.51. Adjusted diluted earnings per share in the prior-year period was $0.55.

 


 

COVID-19 Actions

“We are incredibly proud of the agility, flexibility and dedication demonstrated by our team in these challenging times,” said Eyler.  “I want to thank our more than 11,000 global employees for their strong execution, which has allowed us to keep successfully delivering on our commitments to our customers, shareholders and other stakeholders.”

 

The COVID-19 pandemic is dramatically affecting the global automotive industry including the temporary suspension of vehicle production across Asia, Europe and North America. The Company moved quickly to take additional actions to further improve its liquidity and financial flexibility.

 

 

Drew down an additional $169 million under its revolving credit facility in March

 

Reprioritized and reducing capital expenditures

 

Reducing discretionary operating expenses

 

Deferring a portion of employee compensation beginning May 1, including a 30-40% deferral at the Executive level and a 20% deferral for other salaried employees

 

Managing working capital with strong discipline to improve cash flow

 

Suspended share repurchases to conserve cash

 

As a result of the unprecedented uncertainty facing the automotive industry and global economy, Gentherm withdrew its 2020 guidance on March 25, 2020 and is not providing an update at this time. However, the Company expects product revenues in the second quarter of 2020 to be significantly lower than the first quarter.

 

In addition, the Company has postponed its Investor event originally scheduled for June 9, 2020 to a future date.

 

Conference Call

 

As previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-877-407-4018 (callers in the U.S.) or +1-201-689-8471 (callers outside this U.S.). The passcode for the live call is 13701725.

 

A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

 

A telephonic replay will be available at approximately 2 hours after the call until 11:59 pm Eastern Time on May 21, 2020. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 13701725.

 

Investor Relations Contact
Yijing Brentano

investors@gentherm.com
(248) 308-1702

 

 


 

Media Contact

Melissa Fischer

media@gentherm.com

248.289.9702

 

About Gentherm

Gentherm (NASDAQ:THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 11,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, North Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.

Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this release are made as of the date hereof or as of the date specified herein and are based on management's reasonable expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause actual results or performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that: COVID-19 and its direct and indirect adverse impacts on the automobile and medical industries and global economy has, and will continue to have, an adverse effect on, among other things, the Company’s financial condition, business operations and stock price; future borrowing availability under the Company’s revolving credit facility is subject to compliance with covenants thereunder, and to the extent that the Company’s financial performance (including consolidated EBITDA) deteriorates due to the COVID-19 impacts or otherwise, the borrowing availability may be substantially less than the full amount of revolving credit facility; the Company’s failure to be in compliance with covenants under the revolving credit facility due to COVID-19 or otherwise could result in an event of default thereunder, and if the lenders thereunder do not agree to amend or waive, the amounts outstanding under the revolving credit facility may be accelerated and may become immediately due and payable; additional financing by accessing the capital markets may not be available on acceptable terms, if at all, due to the impact of COVID-19 and additional indebtedness may harm the Company’s financial position and impact the Company’s ability to comply with covenants under the Company’s revolving credit facility; the Company may not realize the expected benefits from any restructuring initiatives it may pursue as a result of the effects of COVID-19; declines in automobile production may have an adverse impact; sales may not increase and the projected future sales volumes on which the Company manages its business may be inaccurate; new or improved competing products may be developed by competitors with greater resources; customer preferences may shift, including due to the evolving use of automobiles and technology; the Company may lose suppliers or customers; market acceptance of the Company’s existing or new products may decrease; currency exchange rates may change unfavorably; pricing pressures from customers may increase; the macroeconomic environment may present adverse conditions; new products may not be feasible; work stoppages impacting the Company, its suppliers or customers, due to labor matters, civil or political unrest, infectious diseases and epidemics or other reasons,

 


 

could harm the Company’s operations; free trade agreements may be altered or additional tariffs may be implemented; customers may not accept pass-through of tariff costs; the Company may be unable to protect its intellectual property in certain jurisdictions; there may be manufacturing or design defects or other quality issues with the Company’s products; the Company may be unable to effectively implement ongoing restructuring and other cost-savings measures or realize the full amount of estimated savings; the Company’s business may be harmed by security breaches and other disruptions to its IT systems; the Company may be unable to comply with or may incur increased costs associated with complying with domestic and international regulations, which could change in an unfavorable manner; and other adverse conditions in the industries in which the Company operates may negatively affect its results.

The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent quarterly reports, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this release does not include the potential impact of any business combinations,  acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s business and financial results.

Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 


 


 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2020

 

 

2019

 

Product revenues

 

$

228,613

 

 

$

257,921

 

Cost of sales

 

 

162,546

 

 

 

182,614

 

Gross margin

 

 

66,067

 

 

 

75,307

 

Operating expenses:

 

 

 

 

 

 

 

 

Net research and development expenses

 

 

17,760

 

 

 

18,897

 

Selling, general and administrative expenses

 

 

25,840

 

 

 

32,651

 

Restructuring expenses

 

 

3,766

 

 

 

1,914

 

Total operating expenses

 

 

47,366

 

 

 

53,462

 

Operating income

 

 

18,701

 

 

 

21,845

 

Interest expense, net

 

 

(748

)

 

 

(1,368

)

Foreign currency (loss) gain

 

 

(938

)

 

 

203

 

Gain on sale of business

 

 

 

 

 

4,970

 

Impairment loss

 

 

 

 

 

(10,484

)

Other income

 

 

264

 

 

 

143

 

Earnings before income tax

 

 

17,279

 

 

 

15,309

 

Income tax expense

 

 

5,406

 

 

 

6,895

 

Net income

 

$

11,873

 

 

$

8,414

 

Basic earnings per share

 

$

0.36

 

 

$

0.25

 

Diluted earnings per share

 

$

0.36

 

 

$

0.25

 

Weighted average number of shares – basic

 

 

32,693

 

 

 

33,573

 

Weighted average number of shares – diluted

 

 

32,869

 

 

 

33,733

 

 

 


 

GENTHERM INCORPORATED

REVENUE BY PRODUCT CATEGORY

(Unaudited, in thousands)

 

 

 

Three Months Ended

 

 

 

 

 

 

 

March 31,

 

 

 

 

 

 

 

2020

 

 

2019

 

 

% Diff

 

Climate Control Seats (CCS)

 

$

82,528

 

 

$

94,354

 

 

 

(12.5

)%

Seat Heaters

 

 

64,532

 

 

 

73,920

 

 

 

(12.7

)%

Automotive Cables

 

 

22,140

 

 

 

23,749

 

 

 

(6.8

)%

Steering Wheel Heaters

 

 

19,235

 

 

 

16,970

 

 

 

13.3

%

Battery Thermal Management (BTM)

 

 

11,209

 

 

 

10,745

 

 

 

4.3

%

Electronics

 

 

10,376

 

 

 

12,852

 

 

 

(19.3

)%

Other Automotive

 

 

6,452

 

 

 

9,767

 

 

 

(33.9

)%

Subtotal Automotive

 

 

216,472

 

 

 

242,357

 

 

 

(10.7

)%

Medical

 

 

12,141

 

 

 

8,187

 

 

 

48.3

%

GPT

 

 

 

 

 

3,959

 

 

 

(100.0

)%

CSZ-IC

 

 

 

 

 

3,418

 

 

 

(100.0

)%

Subtotal Industrial

 

 

12,141

 

 

 

15,564

 

 

 

(22.0

)%

Total Company

 

$

228,613

 

 

$

257,921

 

 

 

(11.4

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Core Businesses (Automotive and Gentherm Medical)

 

$

228,613

 

 

$

250,544

 

 

 

(8.8

)%

 

 

 


 

GENTHERM INCORPORATED

RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2020

 

 

2019

 

Net income

 

$

11,873

 

 

$

8,414

 

Add back:

 

 

 

 

 

 

 

 

Income tax expense

 

 

5,406

 

 

 

6,895

 

Interest expense

 

 

748

 

 

 

1,368

 

Depreciation and amortization

 

 

10,153

 

 

 

10,980

 

Adjustments:

 

 

 

 

 

 

 

 

Restructuring expense

 

 

3,766

 

 

 

1,914

 

Impairment loss

 

 

 

 

 

10,484

 

Gain on sale of business

 

 

 

 

 

(4,970

)

Acquisition transaction expense

 

 

 

 

 

38

 

Unrealized currency loss (gain)

 

 

765

 

 

 

(994

)

CFO transition expenses

 

 

 

 

 

1,065

 

Adjusted EBITDA

 

$

32,711

 

 

$

35,194

 

 

Use of Non-GAAP Financial Measures

 

In addition to the results reported in accordance with GAAP throughout this release, the Company has provided information regarding adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) and adjusted earnings per share (“Adjusted earnings per share” or “Adjusted EPS”), each, a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Adjusted EPS as earnings adjusted by gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company’s reconciliation of net income to Adjusted EBITDA is provided in this release. The Company’s Reconciliation of Adjusted EPS can be found in the supplemental materials furnished as Exhibit 99.2 to the Company’s Form 8-K dated May 7, 2020 and also is included in the presentation entitled “Q1 2020 Gentherm Incorporated Earnings Conference Presentation,” which can be found on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

 

In evaluating its business, the Company considers and uses Adjusted EBITDA and Adjusted EPS as supplemental measures of its operating performance. Management provides Adjusted EBITDA and Adjusted EPS measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis. Other companies in our industry may calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA or Adjusted EPS in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP.

 

Non-GAAP measures referenced in this release may include estimates of future Adjusted EBITDA and Adjusted EPS. Such forward-looking non-GAAP measures may differ significantly from the corresponding GAAP measures, due to depreciation and amortization, tax expense, and/or interest expense, some or all of which management has not quantified for the future periods.

 


 

GENTHERM INCORPORATED

ACQUISITION TRANSACTION EXPENSES, PURCHASE ACCOUNTING IMPACTS

AND OTHER EFFECTS

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

 

Future Full Year Periods (estimated)

 

 

 

2020

 

 

2019

 

 

2020

 

 

2021

 

 

2022

 

 

2023

 

 

Thereafter

 

Transaction related current expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition transaction expenses

 

$

 

 

$

38

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

Non-cash purchase accounting impacts

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer relationships amortization

 

 

1,596

 

 

 

1,828

 

 

 

6,382

 

 

 

5,832

 

 

 

5,423

 

 

 

3,812

 

 

 

16,485

 

Technology amortization

 

 

439

 

 

 

482

 

 

 

1,755

 

 

 

1,747

 

 

 

1,688

 

 

 

211

 

 

 

680

 

Inventory fair value adjustment

 

 

108

 

 

 

39

 

 

 

432

 

 

 

 

 

 

 

 

 

 

 

 

 

Other effects

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring expenses

 

 

3,766

 

 

 

1,914

 

 

 

3,766

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain on sale of business

 

 

 

 

 

(4,970

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Impairment loss

 

 

 

 

 

10,484

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized currency (gain) loss

 

 

765

 

 

 

(994

)

 

 

765

 

 

 

 

 

 

 

 

 

 

 

 

 

CFO transition

 

 

 

 

 

1,065

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total acquisition transaction expenses, purchase accounting impacts and other effects

 

$

6,674

 

 

$

9,886

 

 

$

13,100

 

 

$

7,579

 

 

$

7,111

 

 

$

4,023

 

 

$

17,165

 

Tax effect of above

 

 

(1,710

)

 

 

212

 

 

 

(2,303

)

 

 

(2,020

)

 

 

(1,891

)

 

 

(1,060

)

 

 

(5,484

)

Net income effect

 

$

4,964

 

 

$

10,098

 

 

$

10,797

 

 

$

5,559

 

 

$

5,220

 

 

$

2,963

 

 

$

11,681

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share - difference

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.16

 

 

$

0.30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

$

0.15

 

 

$

0.30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.52

 

 

$

0.55

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

$

0.51

 

 

$

0.55

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

 

 

 

March 31, 2020

 

 

December 31, 2019

 

ASSETS

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

222,939

 

 

$

50,443

 

Restricted cash

 

 

2,505

 

 

 

2,505

 

Accounts receivable, less allowance of $1,639 and $1,193, respectively

 

 

159,011

 

 

 

159,710

 

Inventory:

 

 

 

 

 

 

 

 

Raw materials

 

 

60,844

 

 

 

61,323

 

Work in process

 

 

6,778

 

 

 

7,444

 

Finished goods

 

 

50,019

 

 

 

49,712

 

Inventory, net

 

 

117,641

 

 

 

118,479

 

Other current assets

 

 

44,941

 

 

 

42,726

 

Total current assets

 

 

547,037

 

 

 

373,863

 

Property and equipment, net

 

 

152,120

 

 

 

160,605

 

Goodwill

 

 

63,894

 

 

 

64,572

 

Other intangible assets, net

 

 

50,062

 

 

 

49,783

 

Operating lease right-of-use assets

 

 

14,991

 

 

 

11,587

 

Deferred income tax assets

 

 

56,032

 

 

 

57,650

 

Other non-current assets

 

 

9,234

 

 

 

9,326

 

Total assets

 

$

893,370

 

 

$

727,386

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

97,065

 

 

$

83,035

 

Current lease liabilities

 

 

4,735

 

 

 

4,586

 

Current maturities of long-term debt

 

 

2,500

 

 

 

2,500

 

Other current liabilities

 

 

67,000

 

 

 

66,583

 

Total current liabilities

 

 

171,300

 

 

 

156,704

 

Long-term debt, less current maturities

 

 

231,667

 

 

 

78,124

 

Pension benefit obligation

 

 

7,619

 

 

 

8,057

 

Non-current lease liabilities

 

 

10,869

 

 

 

6,751

 

Other non-current liabilities

 

 

1,534

 

 

 

5,100

 

Total liabilities

 

$

422,989

 

 

$

254,736

 

Shareholders’ equity:

 

 

 

 

 

 

 

 

Common Stock:

 

 

 

 

 

 

 

 

No par value; 55,000,000 shares authorized, 32,598,854 and 32,674,354 issued and outstanding at March 31, 2020 and December 31, 2019, respectively

 

 

102,059

 

 

 

102,507

 

Paid-in capital

 

 

9,648

 

 

 

10,852

 

Accumulated other comprehensive loss

 

 

(54,931

)

 

 

(42,441

)

Accumulated earnings

 

 

413,605

 

 

 

401,732

 

Total shareholders’ equity

 

 

470,381

 

 

 

472,650

 

Total liabilities and shareholders’ equity

 

$

893,370

 

 

$

727,386

 

 

 


 

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

Operating Activities:

 

 

 

 

 

 

 

 

Net income

 

$

11,873

 

 

$

8,414

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

10,406

 

 

 

11,052

 

Deferred income taxes

 

 

721

 

 

 

1,749

 

Stock based compensation

 

 

1,942

 

 

 

1,968

 

Defined benefit plan expense (income)

 

 

85

 

 

 

(617

)

Allowance for credit losses

 

 

451

 

 

 

229

 

Loss on sale of property and equipment

 

 

119

 

 

 

178

 

Operating lease expense

 

 

1,651

 

 

 

1,333

 

Impairment loss

 

 

 

 

 

10,484

 

Gain on sale of business

 

 

 

 

 

(4,970

)

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(2,491

)

 

 

(8,293

)

Inventory

 

 

(404

)

 

 

(229

)

Other assets

 

 

(4,805

)

 

 

(5,553

)

Accounts payable

 

 

13,540

 

 

 

(2,079

)

Other liabilities

 

 

(3,669

)

 

 

(6,785

)

Net cash provided by operating activities

 

 

29,419

 

 

 

6,881

 

Investing Activities:

 

 

 

 

 

 

 

 

Proceeds from the sale of property and equipment

 

 

34

 

 

 

28

 

Proceeds from divestiture of business

 

 

 

 

 

47,500

 

Acquisition of intangible assets

 

 

(3,141

)

 

 

 

Purchases of property and equipment

 

 

(3,231

)

 

 

(5,150

)

Net cash (used in) provided by investing activities

 

 

(6,338

)

 

 

42,378

 

Financing Activities:

 

 

 

 

 

 

 

 

Borrowing of debt

 

 

169,546

 

 

 

10,428

 

Repayments of debt

 

 

(16,111

)

 

 

(49,627

)

Cash paid for the cancellation of restricted stock

 

 

(404

)

 

 

(376

)

Proceeds from the exercise of Common Stock options

 

 

5,902

 

 

 

214

 

Cash paid for the repurchase of Common Stock

 

 

(9,092

)

 

 

(8,040

)

Net cash provided by (used in) financing activities

 

 

149,841

 

 

 

(47,401

)

Foreign currency effect

 

 

(426

)

 

 

(209

)

Net increase in cash, cash equivalents and restricted cash

 

 

172,496

 

 

 

1,649

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

52,948

 

 

 

39,620

 

Cash, cash equivalents and restricted cash at end of period

 

$

225,444

 

 

$

41,269

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Cash paid for taxes

 

$

3,525

 

 

$

3,466

 

Cash paid for interest

 

$

537

 

 

$

1,252

 

 

 

 

 

 

# # # #